ProQR Therapeutics Board Changes Announced
ProQR Therapeutics announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting as their terms conclude. The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planning. An executive search firm has been engaged to assist ProQR in identifying candidates to be nominated to the Board to support long-term value creation for all its stakeholders.
Trade with 70% Backtested Accuracy
Analyst Views on PRQR
About PRQR
About the author
ProQR Reports FY 2025 Financial Highlights
- Earnings Per Share: ProQR reported a GAAP EPS of €0.40 for FY 2025, indicating a level of profitability despite financial challenges, reflecting ongoing investments in R&D and operations.
- Cash Position: As of December 31, 2025, ProQR held approximately €92.4 million in cash and cash equivalents, a significant decrease from €149.4 million in 2024, indicating increased cash outflows in operations and necessitating a focus on future cash management strategies.
- Operating Cash Usage: The net cash used in operating activities for FY 2025 was €52.8 million, up 44% from €36.4 million in 2024, highlighting pressure on operational expenditures that could impact future financial stability.
- R&D Investment Growth: R&D costs for 2025 were €44.7 million, a 23% increase from €36.4 million last year, demonstrating the company's commitment to technological innovation and product development despite high expenditures.
ProQR Secures CTA Approval for AX-0810 and Plans Virtual Investor and Analyst Event on November 3, 2025
ProQR's Clinical Trial Approval: ProQR Therapeutics has received authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 clinical trial of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP, aimed at treating cholestatic diseases.
Upcoming Investor Event: ProQR will host a virtual event on November 3, 2025, to discuss the safety, pharmacokinetics, and biomarker roadmap for AX-0810, featuring presentations from ProQR management and Professor Henkjan J. Verkade, a key opinion leader in pediatric gastroenterology.
Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
Annual General Meeting Announcement: ProQR Therapeutics will hold its Annual General Meeting of Shareholders on June 3, 2025, in Amsterdam, with relevant documents available on their website and the SEC's site for interested shareholders.
Axiomer™ RNA Editing Technology: ProQR is advancing its Axiomer™ platform, which utilizes ADAR to make precise edits to RNA, potentially leading to new treatments for various diseases by correcting mutations or modulating protein expression.
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
Leadership Appointments: ProQR Therapeutics has appointed Dennis Hom as Chief Financial Officer and Dr. Cristina Lopez Lopez as Chief Medical Officer to enhance its RNA editing technology platform, Axiomer™, as it progresses into clinical development.
Axiomer™ Technology Overview: ProQR's Axiomer™ is a next-generation RNA base editing technology that aims to create new medicines by making specific nucleotide edits in RNA, potentially addressing various diseases with unmet medical needs.
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
ProQR Reports FY 2025 Financial Highlights
- Earnings Per Share: ProQR reported a GAAP EPS of €0.40 for FY 2025, indicating a level of profitability despite financial challenges, reflecting ongoing investments in R&D and operations.
- Cash Position: As of December 31, 2025, ProQR held approximately €92.4 million in cash and cash equivalents, a significant decrease from €149.4 million in 2024, indicating increased cash outflows in operations and necessitating a focus on future cash management strategies.
- Operating Cash Usage: The net cash used in operating activities for FY 2025 was €52.8 million, up 44% from €36.4 million in 2024, highlighting pressure on operational expenditures that could impact future financial stability.
- R&D Investment Growth: R&D costs for 2025 were €44.7 million, a 23% increase from €36.4 million last year, demonstrating the company's commitment to technological innovation and product development despite high expenditures.
ProQR Secures CTA Approval for AX-0810 and Plans Virtual Investor and Analyst Event on November 3, 2025
ProQR's Clinical Trial Approval: ProQR Therapeutics has received authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 clinical trial of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP, aimed at treating cholestatic diseases.
Upcoming Investor Event: ProQR will host a virtual event on November 3, 2025, to discuss the safety, pharmacokinetics, and biomarker roadmap for AX-0810, featuring presentations from ProQR management and Professor Henkjan J. Verkade, a key opinion leader in pediatric gastroenterology.
Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
Annual General Meeting Announcement: ProQR Therapeutics will hold its Annual General Meeting of Shareholders on June 3, 2025, in Amsterdam, with relevant documents available on their website and the SEC's site for interested shareholders.
Axiomer™ RNA Editing Technology: ProQR is advancing its Axiomer™ platform, which utilizes ADAR to make precise edits to RNA, potentially leading to new treatments for various diseases by correcting mutations or modulating protein expression.
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
Leadership Appointments: ProQR Therapeutics has appointed Dennis Hom as Chief Financial Officer and Dr. Cristina Lopez Lopez as Chief Medical Officer to enhance its RNA editing technology platform, Axiomer™, as it progresses into clinical development.
Axiomer™ Technology Overview: ProQR's Axiomer™ is a next-generation RNA base editing technology that aims to create new medicines by making specific nucleotide edits in RNA, potentially addressing various diseases with unmet medical needs.
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
